🩸 Hematology Headlines You Shouldn’t Miss This Week: Major Approvals, Breakthrough Trials, and New Therapies
🚀 From major drug approvals to exciting clinical trial results, this week’s update is packed with groundbreaking news you need to know.
🇨🇦 Sarclisa approved in Canada for newly diagnosed multiple myeloma
🌟 Starton’s STAR-LLD shows 100% clinical response in Phase 1b myeloma trial
💊 Aurobindo’s Eugia wins USFDA approval for dasatinib tablets
🧬 AB Science’s AB8939 earns EMA orphan drug status for AML
🏥 ALX Oncology’s evorpacept achieves 90% response rate in Phase 1 lymphoma study
🎯 Y-mAbs begins first-in-human CD38-SADA radioimmunotherapy trial
🇨🇳 InnoCare’s orelabrutinib approved for first-line CLL/SLL in China
🔥 Takeda’s ADCETRIS receives positive CHMP opinion for advanced Hodgkin lymphoma
🩸 MHRA approves marstacimab for hemophilia A and B with strong bleed reduction
🌍 Sanofi and Sobi renew 5-year humanitarian commitment for hemophilia treatment
🔍 Whether you’re a clinician, researcher, or healthcare strategist, this update keeps you ahead on the frontlines of hematologic and oncologic innovation.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on hematology breakthroughs.
#Hematology #MultipleMyeloma #HodgkinLymphoma #Leukemia #Lymphoma #Hemophilia #BiotechUpdates #ClinicalTrials #MedicalInnovation #LucidQuest #HealthcareNews